Patients in this double-blind study ( n = @ ) , who had completed @ induction cycles ( pemetrexed with cisplatin ) without progressive disease ( PD ) and had an ECOG performance status of @/@ , were randomized @:@ to pemetrexed maintenance ( @ mg/m ( @ ) , day @ ) plus best supportive care ( BSC ) or placebo plus BSC until PD .